VP, Head of Translational Sciences
Alexion
Russell Weiner, PhD, FAAPS, is a globally recognized biopharmaceutical leader with 30+ years experience in biopharmaceutical R&D, translational sciences, precision medicine, regulated bioanalysis, biomarker and companion diagnostic assay development. As VP, Head of Translational Sciences at Alexion , AstraZeneca Rare Diseases, Dr. Weiner oversees rare disease translational strategy, biomarker development, diagnostics and translational operations, supporting discovery through approval and life cycle management.
Dr. Weiner earned his PhD in Biochemistry from Albany Medical College. His career includes leadership roles at major organizations such as Bristol-Myers Squibb, Merck, Daiichi Sankyo, the Bill & Melinda Gates Medical Research Institute, and Takeda. His work has significantly advanced precision medicine approaches for cancer. He contributed to the development of Erbitux® for oncology and the advancement of several immuno-therapeutics, including the checkpoint inhibitors Orencia® for rheumatoid arthritis and Nulojix® for kidney transplantation. Dr. Weiner was also instrumental in the development and approval of pioneering checkpoint inhibitors, Yervoy® and Keytruda®.
An active member of the American Association of Pharmaceutical Scientists (AAPS) for 30+ years, Dr. Weiner currently serves as AAPS President. Known for his sense of humor and dedication to mentorship, Dr. Weiner serves as an Adjunct Faculty, Department of Pharmaceutics at the University of Florida.
Disclosure information not submitted.
Special Poster Collection - Best Poster Award
Monday, November 10, 2025
9:30 AM - 10:25 AM CT